RWA Wealth Partners LLC Lowers Stock Holdings in Avalo Therapeutics, Inc. $AVTX

RWA Wealth Partners LLC lowered its stake in Avalo Therapeutics, Inc. (NASDAQ:AVTX) by 16.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 261,016 shares of the company’s stock after selling 51,763 shares during the period. RWA Wealth Partners LLC’s holdings in Avalo Therapeutics were worth $1,302,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of AVTX. Affinity Asset Advisors LLC grew its position in Avalo Therapeutics by 19.3% in the 1st quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company’s stock valued at $5,264,000 after buying an additional 106,389 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in Avalo Therapeutics during the 1st quarter worth $7,209,000. ADAR1 Capital Management LLC acquired a new stake in shares of Avalo Therapeutics in the 1st quarter worth $80,000. Finally, Allostery Investments LP boosted its holdings in shares of Avalo Therapeutics by 46.1% in the first quarter. Allostery Investments LP now owns 107,141 shares of the company’s stock valued at $858,000 after acquiring an additional 33,827 shares in the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AVTX has been the topic of a number of recent analyst reports. HC Wainwright boosted their price target on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Cowen assumed coverage on Avalo Therapeutics in a report on Friday, September 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on Avalo Therapeutics in a research note on Friday, August 15th. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Tuesday, October 14th. Finally, BTIG Research restated a “buy” rating and issued a $40.00 price target on shares of Avalo Therapeutics in a research note on Monday, September 29th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $31.67.

Avalo Therapeutics Price Performance

AVTX opened at $15.05 on Monday. Avalo Therapeutics, Inc. has a 1-year low of $3.39 and a 1-year high of $19.41. The stock has a market cap of $197.91 million, a P/E ratio of -0.83 and a beta of 0.94. The stock’s 50 day simple moving average is $13.61 and its 200 day simple moving average is $8.55.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.52). Research analysts expect that Avalo Therapeutics, Inc. will post -19.07 EPS for the current fiscal year.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.